A novel engineered strain for synthesizing L-leucine and its applications

By genetically modifying recombinant strains to enhance enzyme activity and introducing NADH kinase, the problems of carbon loss and low reducing power utilization efficiency in the production of L-leucine from traditional multi-carbon compound raw materials have been solved, realizing the efficient synthesis of L-leucine from one-carbon compounds, thus improving yield and economic efficiency.

CN123063328APending Publication Date: 2026-11-10MICROCYTO BIOTECHNOLOGY (BEIJING) CO LTD
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202610855342.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-06-15
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

Existing technologies for producing L-leucine from multi-carbon compounds suffer from significant carbon loss and low reducing power utilization efficiency, resulting in limited synthesis throughput and poor economic efficiency. There are still shortcomings in constructing a reducing power supply system that matches the synthesis of L-leucine while efficiently assimilating one-carbon compounds.

Method used

By genetically modifying the starting strain to enhance the expression and activity of related enzymes, introducing or replacing key genes, a recombinant strain was constructed to synthesize L-leucine using methanol as a raw material. This included enhancing the expression of genes such as acetolactate synthase, acetolactate isomer reductase, dihydroxy acid dehydratase, and isopropyl malate synthase, and introducing NADH kinase to optimize the supply of reducing power.

Benefits of technology

This study achieved efficient synthesis of L-leucine from one-carbon compounds, improving yield and economic efficiency, and solving the problems of carbon loss and low reducing power utilization efficiency of traditional multi-carbon compound raw materials.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
Patent Text Reader

Abstract

This invention discloses a method for constructing one or more engineered strains capable of growing or synthesizing L-leucine using one-carbon feedstocks such as methanol. The engineered strains achieve their target function through the following genetic modification: overexpression of key enzyme genes such as acetolactate synthase and acetolactate isomer reductase in specific methanol-tolerant strains. The modified strains can synthesize L-leucine using methanol as a carbon source, showing significant application potential in fields such as biomanufacturing.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of synthetic biology technology, and more specifically, relates to engineered strains that synthesize L-leucine from one-carbon compounds and their applications. Background Technology

[0002] L-Leucine is an essential branched-chain amino acid for humans and animals, widely used in food, feed, pharmaceuticals, and health products, with significant industrial value, particularly in feed additives and pharmaceutical intermediates. Currently, L-leucine is primarily produced through microbial fermentation, typically using multi-carbon compounds such as glucose, starch hydrolysate, or molasses as carbon sources. However, this traditional production method not only relies on grain resources and incurs high costs, but also suffers from significant carbon loss and low reducing power utilization efficiency during fermentation, limiting product yield and economic viability.

[0003] Within microorganisms, L-leucine is generated from pyruvate via acetolactate synthesis, α-isopropylmalate synthesis, and subsequent conversion steps. Many of these reactions rely on a continuous supply of reducing cofactors such as NADPH. Insufficient reducing power directly limits the synthetic flux and induces carbon diversion to the byproduct pathway. Furthermore, key enzymes in the L-leucine biosynthesis pathway are generally subject to feedback inhibition and transcriptional regulation, making them highly sensitive to intracellular reducing power status. Therefore, the imbalance between reducing power supply and demand becomes a critical factor restricting efficient synthesis.

[0004] In recent years, biomanufacturing technologies utilizing one-carbon compounds as substrates have gradually emerged. One-carbon compounds are widely available, inexpensive, and do not compete with food resources; their oxidation and assimilation processes can significantly influence the generation and distribution of reducing power within cells. However, current technologies still have significant shortcomings in constructing a reducing power supply system that matches L-leucine synthesis while efficiently assimilating one-carbon compounds. There is an urgent need to develop engineered strains and their applications that can coordinate carbon metabolism and reducing power balance to achieve efficient L-leucine synthesis. Summary of the Invention

[0005] The technical problem to be solved by this invention is: how to synthesize L-leucine from one-carbon compounds.

[0006] To solve the above-mentioned technical problems, the present invention provides the following technical solutions:

[0007] In a first aspect, the present invention provides a recombinant bacterium capable of synthesizing L-leucine from methanol. The recombinant bacterium is obtained by modifying the starting strain by at least one of the following modifications (1)-(9):

[0008] (1) Enhance the gene expression level of acetolactate synthase and / or enhance its enzyme activity or content;

[0009] (2) Enhance the gene expression level of acetolactate isomer reductase and / or enhance its enzyme activity or content;

[0010] (3) Enhance the gene expression level of dihydroxy acid dehydratase, and / or enhance its enzyme activity or content;

[0011] (4) Enhance the gene expression level of isopropyl malate synthase and / or enhance its enzyme activity or content;

[0012] (5) Enhance the gene expression level of isopropyl malate isomerase and / or enhance its enzyme activity or content;

[0013] (6) Enhance the gene expression level of isopropyl malate dehydrogenase, and / or enhance its enzyme activity or content;

[0014] (7) Enhance the gene expression level of branched-chain amino acid transaminases, and / or enhance their enzyme activity or content;

[0015] (8) Introduce the L-leucine efflux protein gene and / or introduce a substance with the activity of this protein;

[0016] (9) Introduce the NADH kinase gene and / or introduce a substance with the activity of the enzyme.

[0017] Furthermore, the starting strain is a strain with methanol tolerance characteristics.

[0018] Furthermore, the methanol-tolerant strain can be a recombinant *Escherichia coli*. Even further, the recombinant *Escherichia coli* can be an *Escherichia coli* strain that has been artificially modified to possess a methanol utilization metabolic pathway. In some specific embodiments of the present invention, the recombinant *Escherichia coli* is *Escherichia coli* strain GL05 (accession number: CGMCC No. 35139).

[0019] The specific modification of (1) above can be: knocking out the gene (yghX) encoding the hydrolase and replacing it with the expression cassette (ilvBN) of the acetolactate synthase gene.

[0020] The modifications described in (2)-(3) above can be as follows: knock out the gene (livH) encoding the branched-chain amino acid uptake protein and replace it with the expression frames of the acetyllactone isomer reductase gene (ilvC) and the dihydroxy acid dehydratase gene (ilvD);

[0021] The modifications described in (4)-(6) above can be specifically implemented by introducing the expression frames encoding the isopropyl malate synthase gene (leuA), isopropyl malate isomerase gene (leuCD), and isopropyl malate dehydrogenase gene (leuB) into biological cells in the form of plasmids.

[0022] The above (7) modification can specifically be to replace the promoter of branched-chain amino acid transaminase (ilvE) with P119;

[0023] The above (8) modification can specifically be to replace the promoter of L-leucine efflux protein (leuE) with P119;

[0024] The specific modification of (9) above can be: knocking out the gene (lpxM) encoding myristyltransferase and replacing it with the expression cassette of the NADH kinase gene (pos5).

[0025] Furthermore, the NADH kinase (pos5) is derived from Saccharomyces cerevisiae.

[0026] The nucleotide sequence of the P119 promoter is SEQ ID No. 2; the NCBI reference sequence number of the large subunit of acetolactate synthase (ilvB) is NP_418127.1, and the NCBI reference sequence number of its encoding gene is Gene ID: 948182 (2025.12.09); the NCBI reference sequence number of the small subunit of acetolactate synthase (ilvN) is NP_418126.1, and the NCBI reference sequence number of its encoding gene is Gene ID: 948183 (2025.12.09); the NCBI reference sequence number of acetolactate isomer reductase (ilvC) is NP_418222.1, and the NCBI reference sequence number of its encoding gene is Gene ID: 948286 (2025.12.09); the NCBI reference sequence number of the dihydroxy acid dehydrase (ilvD) is YP_026248.1, and the NCBI reference sequence number of its encoding gene is Gene ID: 948182 (2025.12.09). The reference sequence number is Gene ID: 948277 (2025.12.09); the NCBI reference sequence number for the isopropyl malate synthase (leuA) is NP_414616.1, and the NCBI reference sequence number for its encoding gene is Gene ID: 947465 (2025.12.09); the NCBI reference sequence number for the large subunit of the isopropyl malate isomerase (leuC) is NP_414614.1, and the NCBI reference sequence number for its encoding gene is Gene ID: 945076 (2025.12.09); the NCBI reference sequence number for the small subunit of the isopropyl malate isomerase (leuD) is NP_414613.1, and the NCBI reference sequence number for its encoding gene is Gene ID: 945642 (2025.12.09); the NCBI reference sequence number for the isopropyl malate dehydrogenase (leuB) is... The reference sequence number is NP_414615.4, and its encoding gene's NCBI reference sequence number is Gene ID: 944798 (2025.12.09); the NCBI reference sequence number for the branched-chain amino acid transaminase (ilvE) is YP_026247.1, and its encoding gene's NCBI reference sequence number is Gene ID: 948278 (2025.12.09); the NCBI reference sequence number for the L-leucine efflux protein (leuE) is NP_416312.1, and its encoding gene's NCBI reference sequence number is Gene ID: 946157 (2025.12.09); the NADH kinase (pos5) is derived from *Saccharomyces cerevisiae*, and its NCBI reference sequence number is NP_015136.1, and its encoding gene's NCBI reference sequence number is Gene ID: 855913 (2026.1.24).

[0027] Furthermore, the methanol-tolerant strain can also be a Bacillus. Even further, the Bacillus can be Bacillus methanolicus. It can also be other naturally occurring or artificially modified Bacillus strains that already possess methanol utilization metabolic responses. In some specific embodiments of the present invention, the Bacillus is Bacillus strain YW01 (accession number: CGMCC No. 37312).

[0028] The modifications described in (1)-(3) above can be as follows: the expression frames encoding the acetolactate synthase gene (BmilvBH), acetolactate isomer reductase gene (BmilvC), and dihydroxy acid dehydratase gene (BmilvD) are introduced into biological cells in the form of plasmids.

[0029] The modifications described in (4)-(6) above can be as follows: knock out the gene encoding acetyl-CoA synthase 2 (acsA2) and replace it with expression frames for isopropyl malate synthase gene (BmleuA), isopropyl malate isomerase gene (BmleuCD), and isopropyl malate dehydrogenase gene (BmleuB).

[0030] The modifications described in (7)-(8) above can be as follows: integrating the expression frames of the branched-chain amino acid transaminase gene (BmilvE) and the L-leucine efflux transport protein gene (leuE) into the pflB site of the gene encoding pyruvate formate lyase.

[0031] The modification in (9) above can be as follows: knock out the gene (acsA1) encoding acetyl-CoA synthase 1 and replace it with the expression cassette of the NADH kinase gene (pos5).

[0032] Furthermore, the acetolactate synthase large subunit gene (BmilvB), acetolactate synthase small subunit gene (BmilvH), acetolactate isomer reductase gene (BmilvC), dihydroxy acid dehydrase gene (BmilvD), isopropyl malate synthase gene (BmleuA), isopropyl malate isomerase large subunit gene (BmleuC), isopropyl malate isomerase small subunit gene (BmleuD), isopropyl malate dehydrogenase gene (BmleuB), and branched-chain amino acid transaminase gene (BmilvE) are derived from Bacillus methanolicus; the L-leucine efflux transporter gene (leuE) is derived from Escherichia coli; and the NADH kinase gene (pos5) is derived from Saccharomyces cerevisiae.

[0033] The NCBI reference sequence number for the large subunit of acetolactate synthase (BmilvB) is AIE60946.1, and the NCBI reference sequence number for its encoding gene is CP007739.1:2541922..2543637 (complement) (2023.11.09); the NCBI reference sequence number for the small subunit of acetolactate synthase (BmilvH) is AIE60945.1, and the NCBI reference sequence number for its encoding gene is CP007739.1:2541407..2541925 (complement) (2023.11.09); the NCBI reference sequence number for the acetolactate isomer reductase (BmilvC) is AIE60944.1, and the NCBI reference sequence number for its encoding gene is CP007739.1:2540349..2541371. (complement) (2023.11.09); The NCBI reference sequence number of the dihydroxy acid dehydratase (BmilvD) is AIE60451.1, and the NCBI reference sequence number of its encoding gene is CP007739.1:2038255..2039967 (complement) (2023.11.09); The NCBI reference sequence number of the isopropyl malate synthase (BmleuA) is AIE60940.1, and the NCBI reference sequence number of its encoding gene is CP007739.1:2535500..2536090 (complement) (2023.11.09); The NCBI reference sequence number of the large subunit of isopropyl malate isomerase (BmleuC) is AIE60941.1, and the NCBI reference sequence number of its encoding gene is CP007739.1:2536106..2537518 (complement) (2023.11.09); The NCBI reference sequence number of the small subunit of isopropyl malate isomerase (BmleuD) is AIE60940.1, and the NCBI reference sequence number of its encoding gene is CP007739.1:2535500..2536090 (complement) (2023.11.09); The NCBI reference sequence number of the isopropyl malate dehydrogenase (BmleuB) is AIE60942.1, and the NCBI reference sequence number of its encoding gene is CP007739.1:2536106..2537518 (complement) (2023.11.09); The NCBI reference sequence number of the small subunit of isopropyl malate isomerase (BmleuB) is AIE60942.1, and the NCBI reference sequence number of its encoding gene is CP007739.1:2535500..2536090 (complement) (2023.11.09); The NCBI reference sequence number of the small subunit of isopropyl malate isomerase (BmleuB) is AIE60941.1, and the NCBI reference sequence number of its encoding gene is CP007739.1:2536106..2537518 (complement) (2023.11.09); The NCBI reference sequence number of the small subunit of isopropyl malate isomerase (BmleuB) is The reference sequence number is CP007739.1:2537700..2538797 (complement) (2023.11.09); the NCBI reference sequence number of the branched-chain amino acid transaminase (BmilvE) is AIE60947.1, and the NCBI reference sequence number of its encoding gene is CP007739.1:2543986..2544891 (complement) (2023).11.09); the NCBI reference sequence number of the L-leucine efflux protein (leuE) is NP_416312.1, and the NCBI reference sequence number of its encoding gene is Gene ID: 946157 (2025.12.09); the NADH kinase (pos5) is derived from *Saccharomyces cerevisiae*, with NCBI reference sequence number NP_015136.1, and the NCBI reference sequence number of its encoding gene is Gene ID: 855913 (2026.1.24).

[0034] Furthermore, the methanol-tolerant strain can also be a yeast. More specifically, the yeast can be *Pichia pastoris* (classified as *Komagataella phaffii*) or *Hansenula polymorpha* (classified as *Candida parapolymorpha*). It can also be other naturally occurring or artificially modified yeast strains that already possess methanol utilization metabolism. In some specific embodiments of the present invention, the yeast serving as the recipient strain is *Hansenula polymorpha* strain AP17 (accession number: CGMCC No. 39154).

[0035] The modification of (1) above can specifically be: inserting the expression cassette of the acetolactate synthase gene (OpALS) into the integration site CIS1;

[0036] The modifications described in (2)-(3) above can be as follows: inserting expression frames of acetolactate isoreductase gene (OpilvC) and dihydroxy acid dehydratase gene (OpilvD) into the integration site CIS2.

[0037] The modifications described in (4)-(6) above can be as follows: the gene for acetyl-CoA synthase 1 (acsA1) is inserted into the integration site CIS4 and knocked out, and replaced with expression frames for isopropyl malate synthase (OpleuA), isopropyl malate isomerase (OpleuC), and isopropyl malate dehydrogenase (OpleuB).

[0038] The modifications described in (7)-(8) above can specifically be: inserting the expression frames of branched-chain amino acid transaminase gene (OpilvE) and L-leucine efflux protein gene (leuE) into the integration site CIS3;

[0039] The modification in (9) above can specifically be: inserting the expression cassette of the NADH kinase gene (pos5) into the integration site CIS5;

[0040] Furthermore, the L-leucine efflux transporter gene (leuE) is derived from *Escherichia coli*; and the NADH kinase (pos5) is derived from *Saccharomyces cerevisiae*.

[0041] The NCBI reference sequence number for the large subunit of acetolactate synthase (Opals1) is XP_013932258.1, and the NCBI reference sequence number for its encoding gene is Gene ID: 25771930 (2023.02.17); the NCBI reference sequence number for the small subunit (Opals2) is XP_013933317.1, and the NCBI reference sequence number for its encoding gene is Gene ID: 25770799 (2025.07.09); the NCBI reference sequence number for the acetolactate isomer reductase (OpilvC) is XP_013932677.1, and the NCBI reference sequence number for its encoding gene is Gene ID: 25772325 (2025.07.09); the NCBI reference sequence number for the dihydroxy acid dehydratase (OpilvD) is... The NCBI reference sequence number for the gene encoding the branched-chain amino acid transaminase (OpilvE) is XP_013932746.1, and its NCBI reference sequence number is Gene ID: 25771717 (July 9, 2025). The NCBI reference sequence number for the branched-chain amino acid transaminase (OpilvE) is XP_013932746.1, and its NCBI reference sequence number is Gene ID: 25772389 (July 9, 2025). The NCBI reference sequence number for the isopropyl malate synthase (OpleuA) is XP_013937328.1, and its NCBI reference sequence number is Gene ID: 25771685 (July 9, 2025). The NCBI reference sequence number for the isopropyl malate isomerase (OpleuC) is XP_013932221.1, and its NCBI reference sequence number is Gene ID: 25771895 (2025.07.09); the NCBI reference sequence number of the isopropyl malate dehydrogenase (OpleuB) is XP_013937220.1, and the NCBI reference sequence number of its encoding gene is Gene ID: 25771585 (2025.07.09); the NCBI reference sequence number of the L-leucine efflux protein (leuE) is NP_416312.1, and the NCBI reference sequence number of its encoding gene is Gene ID: 946157 (2025.12.09); the NADH kinase (pos5) is derived from Saccharomyces cerevisiae, and its NCBI reference sequence number is NP_015136.1, and the NCBI reference sequence number of its encoding gene is Gene ID: 855913 (2026.1.24).

[0042] In a second aspect, the present invention provides a recombinant bacterium, wherein the recombination is obtained by further modifying the recombinant bacterium described in the first aspect by at least one of the following modifications (10)-(12):

[0043] (10) Introduce the 3-phosphoglycerate phosphatase gene (pgp) and / or introduce a substance with the activity of this enzyme;

[0044] (11) Introduce the hydroxypyruvate dehydrogenase (hpdA) gene and / or introduce a substance with the activity of this enzyme;

[0045] (12) Introduce the xylulose 5-phosphate synthase (xps) gene and / or introduce a substance with the activity of the enzyme.

[0046] In a specific embodiment of the present invention using Escherichia coli GL05 strain as the starting strain, the modifications described above (10)-(12) can specifically be: knocking out the gene encoding acetate kinase (ackA) and replacing it with expression frames for the gene encoding 3-phosphoglycerate phosphatase (pgp), hydroxypyruvate dehydrogenase (hpdA), and xylulose 5-phosphate synthase (xps).

[0047] The amino acid sequence of the 3-phosphoglycerate phosphatase gene (pgp) is shown in SEQ ID NO.18, and the encoding gene sequence is shown in SEQ ID NO.24; the amino acid sequence of the hydroxypyruvate dehydrogenase gene (hpdA) is shown in SEQ ID NO.19, and the encoding gene sequence is shown in SEQ ID NO.25; the amino acid sequence of the 5-phosphoxulose synthase gene (xps) is shown in SEQ ID NO.20, and the encoding gene sequence is shown in SEQ ID NO.26.

[0048] In a specific embodiment of the present invention using Bacillus strain YW01 as the starting strain, the modifications described above (10)-(12) can be as follows: In the modification using Bacillus strain YW01 as the starting strain, the gene encoding acetyl-CoA synthase 3 (acsA3) is further knocked out and replaced with expression frames of 3-phosphoglycerate phosphatase gene (pgp), hydroxypyruvate dehydrogenase gene (hpdA) and 5-phosphoxulose synthase gene (xps).

[0049] The amino acid sequence of the 3-phosphoglycerate phosphatase gene (pgp) is shown in SEQ ID NO.18, and the encoding gene sequence is shown in SEQ ID NO.24; the amino acid sequence of the hydroxypyruvate dehydrogenase gene (hpdA) is shown in SEQ ID NO.19, and the encoding gene sequence is shown in SEQ ID NO.25; the amino acid sequence of the 5-phosphoxulose synthase gene (xps) is shown in SEQ ID NO.20, and the encoding gene sequence is shown in SEQ ID NO.26.

[0050] In a specific embodiment of the present invention using Hansenula polymorpha AP17 strain as the starting strain, the modifications described above (10)-(12) can be as follows: In the modification using Hansenula polymorpha AP17 strain as the starting strain, the expression frames of the 3-phosphoglycerate phosphatase gene (pgp), hydroxypyruvate dehydrogenase gene (hpdA) and 5-phosphoxulose synthase gene (xps) are further inserted at the integration site CIS8.

[0051] The amino acid sequence of the 3-phosphoglycerate phosphatase gene (pgp) is shown in SEQ ID NO.21, and the encoding gene sequence is shown in SEQ ID NO.24; the amino acid sequence of the hydroxypyruvate dehydrogenase gene (hpdA) is shown in SEQ ID NO.22, and the encoding gene sequence is shown in SEQ ID NO.25; the amino acid sequence of the 5-phosphoxulose synthase gene (xps) is shown in SEQ ID NO.23, and the encoding gene sequence is shown in SEQ ID NO.26.

[0052] Thirdly, the present invention provides a method for constructing a recombinant bacterium that can increase L-leucine production, the method comprising the step of modifying the starting strain according to the modification (1)-(9) described in the first aspect.

[0053] Fourthly, the present invention provides a method for constructing a recombinant bacterium capable of increasing L-leucine production, the method comprising the steps of modifying the starting strain according to the modifications (1)-(9) of the first aspect, and the steps of modifying according to the modifications (10)-(12) of the second aspect.

[0054] Fifthly, the present invention provides the use of the recombinant bacteria described in any one of the first to fourth aspects in the production or improvement of L-leucine yield.

[0055] In a sixth aspect, the present invention provides a method for producing or increasing the yield of L-leucine, comprising the following steps: using methanol or formaldehyde as raw material, culturing the recombinant bacteria described in any one of the first to fourth aspects, collecting the culture, and obtaining L-leucine.

[0056] In this invention, the methanol feedstock can be derived from carbon dioxide and carbon dioxide-containing gases. Specifically, hydrogen can be generated by electrolyzing water, and then methanol can be synthesized from hydrogen and carbon dioxide through a chemical reaction.

[0057] The above-mentioned products may be bacterial agents containing the recombinant bacteria or / and cultures of the recombinant bacteria.

[0058] The term "culture" refers to a liquid or solid product (i.e., fermentation product) that has grown a microbial community after artificial inoculation and cultivation. It is a product obtained by growing and / or amplifying microorganisms; it can be a biologically pure culture of microorganisms, or it can contain a certain amount of culture medium, metabolites, or other components produced during the cultivation process.

[0059] The beneficial technical effects achieved by this invention are as follows:

[0060] This invention provides a recombinant bacterium that can efficiently synthesize L-leucine using raw materials such as methanol and formaldehyde, and establishes a route for synthesizing L-leucine using carbon dioxide, methanol, formaldehyde, etc., which has great economic and social value. Preservation Instructions

[0061] (1) Strain name: Hansenula polymorpha

[0062] Latin name: Ogataea parapolymorpha

[0063] Strain number: AP17

[0064] Preservation Institution: CGMCC - China General Microbiological Culture Collection Center

[0065] Address: No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing

[0066] Deposit date: March 11, 2026

[0067] CGMCC Registration Number: CGMCC No. 39154

[0068] (2) Bacterial strain name: Escherichia coli

[0069] Latin name: Escherichia coli

[0070] Strain number: GL05

[0071] Preservation Institution: CGMCC - China General Microbiological Culture Collection Center

[0072] Address: No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing

[0073] Deposit date: July 8, 2025

[0074] CGMCC Registration Number: CGMCC No. 35139

[0075] (3) Strain name: Bacillus

[0076] Latin name: Bacillus sp.

[0077] Strain number: YW01

[0078] Preservation Institution: CGMCC - China General Microbiological Culture Collection Center

[0079] Address: No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing

[0080] Deposit date: January 7, 2026

[0081] CGMCC Registration Number: CGMCC No. 37312 Attached Figure Description

[0082] To more clearly illustrate the specific embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the specific embodiments or the prior art will be briefly introduced below. Obviously, the drawings described below are some embodiments of the present invention. For those skilled in the art, other drawings can be obtained from these drawings without creative effort.

[0083] Figure 1 The HPLC elution chromatogram of L-leucine (sample). Detailed Implementation

[0084] The present invention will now be described in further detail with reference to specific embodiments. The given embodiments are merely illustrative of the invention and not intended to limit its scope. The embodiments provided below can serve as a guide for further improvements by those skilled in the art and do not constitute a limitation on the invention in any way.

[0085] Unless otherwise specified, the experimental methods used in the following examples are conventional methods, performed according to the techniques or conditions described in the literature in this field or according to the product instructions. Unless otherwise specified, the materials and reagents used in the following examples are commercially available.

[0086] In the following examples, the yeast used as the recipient strain can be *Pichia pastoris* GS115, *Pichia pastoris* PP208, *Hansenula polymorpha* DL-1, or *Hansenula polymorpha* AP17. *Pichia pastoris* GS115 can be purchased from Invitrogen (catalog number C18100); *Hansenula polymorpha* DL-1 can be obtained from the American Type Culture Collection (ATCC) (number 26012); *Pichia pastoris* PP208 is described in patent CN119040152A, which is further derived from *Pichia pastoris* GS115, and can be constructed using *Pichia pastoris* GS115 as the starting strain according to patent CN119040152A. The PP208 strain already exhibits the following characteristics: enhanced expression of the alcohol oxidase (AOX) gene, dihydroxyacetone synthase (DAS) gene, dihydroxyacetone kinase (DAK) gene, and triose phosphate isomerase (TPI) gene. The *Hansenula polymorpha* AP17 strain is further derived from the *Hansenula polymorpha* DL-1 strain. The AP17 strain already exhibits the following characteristics: enhanced expression of the alcohol oxidase (AOX) gene, dihydroxyacetone synthase (DAS) gene, dihydroxyacetone kinase (DAK) gene, and triose phosphate isomerase (TPI) gene. *Hansenula polymorpha* AP17 is deposited at the China General Microbiological Culture Collection Center (CGMCC) (accession number CGMCC No. 39154). For specific construction methods, please refer to the applicant's patent application (application number: 202610482275.6; application date: April 13, 2026).

[0087] In the following examples, the *Escherichia coli* strain used as the recipient bacterium may be GL05. The *E. coli* GL05 strain is further derived from the *E. coli* MG1655 strain. The GL05 strain already includes the following characteristics: the introduction of the methanol dehydrogenase (MDH) gene, 3-hexylose-6-phosphate synthase (HPS), and 6-phosphate-3-hexose isomerase (PHI). *E. coli* GL05 is deposited at the China General Microbiological Culture Collection Center (CGMCC) (accession number CGMCC No. 35139). For specific construction methods, please refer to the applicant's patent application (application number: 202610394842.2; application date: March 29, 2026).

[0088] In the following examples, the Bacillus species used as recipient bacteria may be *Bacillus methanolica* PB1, *Bacillus methanolica* MGA3, *Bacillus methanolica* YL23, or *Bacillus methanolica* YW01. *Bacillus methanolica* PB1 can be obtained from the American Type Culture Collection (ATCC) (No. 51375). *Bacillus methanolica* MGA3 can be obtained from the American Type Culture Collection (ATCC) (No. 53907). *Bacillus methanolica* strain YL23 is described in patent CN120519332A. Strain YL23 already includes the following characteristics: presence of the methanol dehydrogenase (MDH) gene, 3-hexylose-6-phosphate synthase (HPS), and 6-phosphate-3-hexose isomerase (PHI). *Bacillus methanolica* YL23 is deposited at the China General Microbiological Culture Collection Center (CGMCC) (accession number CGMCC No. 29579). Strain YW01 is further derived from *Bacillus methanolica* strain YL23. Bacillus YW01 is deposited at the China General Microbiological Culture Collection Center (CGMCC) (accession number CGMCC No. 37312). For the specific construction method, please refer to the applicant's patent application (application number: 202610394839.0; application date: March 29, 2026).

[0089] In the following examples, plasmid pKD46 (CGSC#: 7739) is a product of the E. coli Genetic Depository, Yale University, USA (CGSC). The sequence information of plasmid pYB1k is described in patent CN119799606A. The sequence information of plasmid pSCre is described in patent CN120485085A. The sequence information of plasmid pPCCas is described in patent CN119040152A. The sequence of plasmid pYWCC12 is as shown in SEQ ID NO.46, and the specific construction method can be found in the applicant's patent application (application number: 202610394839.0; application date: March 29, 2026). Plasmid pYB1k contains an arabinose promoter for the expression of exogenous genes. The sequence of plasmid pUC57 can be found in GenBank: Y14837.1 (February 11, 1999) in the NCBI database. The pUC57 plasmid is a cloning vector; during gene synthesis, the synthesized gene is directly inserted into the EcoRV site of the pUC57 plasmid. The pKD46 and pSCre plasmids contain the temperature-sensitive origin of replication oriR101, which replicates normally at 30°C but is automatically lost at temperatures above 37°C. The pKD46 plasmid contains Gam, Exo, and Beta proteins, used to mediate syngenomic replication, while the pSCre plasmid contains Cre recombinase, used for the elimination of selectable marker genes. The pPCCas plasmid is used as a tool plasmid for gene editing in *Hansenula polymorpha*. The pYWCC12 plasmid is used as a tool plasmid for gene editing in *Bacillus*.

[0090] T4 DNA Ligase (Catalog No. M0202V), BbsⅠ-HF (Catalog No. R3539S), and DpnⅠ (Catalog No. R0176L) were purchased from NEB. The DNA gel rapid purification kit (Catalog No. EG101-02) was purchased from TransGen.

[0091] The sequences of the DNA fragments and primers involved in each embodiment of the present invention are detailed in Tables 1 and 2, respectively.

[0092] Table 1. List of Sequence Fragments

[0093] Segment Name Sequence information Segment Name Sequence information Segment Name Sequence information LKL SEQ ID NO.1 P119 SEQ ID NO.2 Ptrc SEQ ID NO.3 RBS1 SEQ ID NO.4 TrrnB SEQ ID NO.5 ilvEup SEQ ID NO.6 ilvEdown SEQ ID NO.7 leuEup SEQ ID NO.8 leuEdown SEQ ID NO.9 yghXup SEQ ID NO.10 yghXdown SEQ ID NO.11 livHup SEQ ID NO.12 livHdown SEQ ID NO.13 lpxMup SEQ ID NO.14 lpxMdown SEQ ID NO.15 ackAup SEQ ID NO.16 ackAdown SEQ ID NO.17 pgp1 SEQ ID NO.18 hpdA1 SEQ ID NO.19 xps1 SEQ ID NO.20 pgp2 SEQ ID NO.21 hpdA2 SEQ ID NO.22 XPS2 SEQ ID NO.23 Pmdh SEQ ID NO.27 Tmdh SEQ ID NO.28 pflB_HRup SEQ ID NO.29 pflB_HRdw SEQ ID NO.30 RBS2 SEQ ID NO.31 acsA1_HRup SEQ ID NO.32 acsA1_HRdw SEQ ID NO.33 acsA2_HRup SEQ ID NO.34 acsA2_HRdw SEQ ID NO.35 acsA3_HRup SEQ ID NO.36 acsA3_HRdw SEQ ID NO.37 gpflB SEQ ID NO.38 gacsA1 SEQ ID NO.39 gacsA2 SEQ ID NO.40 gacsA3 SEQ ID NO.41 PMOX SEQ ID NO.42 TMOX SEQ ID NO.43 SgCIS1 SEQ ID NO.44 CIS1up SEQ ID NO.45 CIS1down SEQ ID NO.46 SgCIS2 SEQ ID NO.47 CIS2up SEQ ID NO.48 CIS2down SEQ ID NO.49 SgCIS3 SEQ ID NO.50 CIS3up SEQ ID NO.51 CIS3down SEQ ID NO.52 SgCIS4 SEQ ID NO.53 CIS4up SEQ ID NO.54 CIS4down SEQ ID NO.55 SgCIS5 SEQ ID NO.56 CIS5up SEQ ID NO.57 CIS5down SEQ ID NO.58 SgCIS8 SEQ ID NO.59 CIS8up SEQ ID NO.60 CIS8down SEQ ID NO.61 pYWCC12 SEQ ID NO.62 pos5 Gene ID: 855913 leuE Gene ID: 946157 ilvB Gene ID: 948182 ilvN Gene ID: 948183 ilvC Gene ID: 948286 ilvD Gene ID: 948277 ilvE Gene ID: 948278 leuA Gene ID: 947465 leuB Gene ID: 944798 leuC Gene ID: 945076 leuD Gene ID: 945642 BmilvB CP007739.1:2541922..2543637(complement) BmilvH CP007739.1:2541407..2541925(complement) BmilvC CP007739.1:2540349..2541371(complement) BmilvD CP007739.1:2038255..2039967(complement) BmleuA CP007739.1:253500..2536090(complement) BmleuC CP007739.1:2536106..2537518(complement) BmleuD CP007739.1:2535500..2536090(complement) BmleuB CP007739.1:2537700..2538797(complement) BmilvE CP007739.1:2543986..2544891(complement) Opals1 Gene ID: 25771930 Opals2 Gene ID: 25770799 OpilvC Gene ID:25772325 OpilvD Gene ID: 25771717 OpilvE Gene ID: 25772389 OpleuA Gene ID:25771685 OpleuC Gene ID: 25771895 OpleuB Gene ID: 25771585

[0094] Table 2 Primer Sequences

[0095] Primer or sequence name Nucleotide sequence (5' to 3') <![CDATA[ kan-R ]]> <![CDATA[ tcgtcaagaaggcgatagaa ]]> ilvE-1 taaactggtggacgtcgcacacgt ilvE-2 gcaccttcgcgtcttcccagc ilvE-3 cttactgtttagtcagttaaa leuE-1 agccgctacagattggtta leuE-2 gcaccaacacaataaaaa leuE-3 cctgatttctccttttct yghX-1 cagtgtccttttgccaggca yghX-2 gctcaagccaaattatgcgct yghX-3 caggagagattatcgaaccattt livH-1 gttcatccacggcagccaagtgatca livH-2 cccataaagacgcccgccag livH-3 ggtgtcttccagtggcacgccgacg lpxM-1 agttcaacagatttcgaatattctgaagca lpxM-2 ccggtacgcagtcagtaccggcttttttta lpxM-3 aacgccacatccggcctacagttcaatgat ackA-1 tgcagtgcatgatgttaatcataaatgtcg ackA-2 gtgtcatcatgcgctacgctctatggctcc ackA-3 tatcctctttcgttaccgccgatttggcgg leuA-F cacacaggaaacagaatgagccagcaagtca leuD-R agcttgcatgcctgcaggtcgactcttaattcataaacgcaggttgttttgct pTrc99a-01F gagtcgacctgcaggcatgcaagcttggct pTrc99a-01R tctgtttcctgtgtgaaattgttatccgct RV-M ttatgaatcgtcgtgcagatctggttcata pTrcHis-R attctgttttatcagaccgcttctgcgttc pYW_F tgtgaaaattgcgttgcgct pYW_R caggaaacagctatgaccatgattacg gpflB_F gtagatcttgaaggtccgactgaagctaca gpflB_R attgactgtagcttcagtcggaccttcaag pflB-F atggtcatagctgtttcctgggcatatgcttgtaatgg pflB-R agcgcaacgcaatttcacacgatgttcattgtcaatac pflB-U ggggatttcccaacacatg pflB-D cattggtcattcgtttctcc gacsA1_F gtagatgatgacaatggagcaccgctctc gacsA1_R attgacgaggaagcggtgctccattgtcatc acsA1-F atggtcatagctgtttcctgcttggactgggatggatgtttgttgcgcc acsA1-R agcgcaacgcaattttcacattgaacatcttcgacatgaaataatggatg acsA1-U agtcggaatccgcagcggt acsA1-D tctgcatcgatggaaacagcatt gacsA2_F gtagataccctgaaacgtggtacaaaatgat gacsA2_R attgacatcatttgtaccacgtttcagggt acsA2-F atggtcatagctgtttcctggccttgctatgattctctccttc acsA2-R agcgcaacgcaattttcacaatcttatgattcctggtttg acsA2-U cctacaattgtttgccttt acsA2-D gaaagactggaacaggaaat gacsA3_F agattaccgggatggttcccgcaatga gacsA3_R tgactcattgcgggaaccatcccggtaa acsA3-F atggtcatagctgtttcctgacaagctctccataatttccggaaaaagc acsA3-R agcgcaacgcaatttcacaaaaaattttagttctgagaataagcttgc acsA3-U tggattcttatttgctgaaatggtgcttg acsA3-D ttacagcggaatgttatcatgttttttgcg <![CDATA[ pNW_F ]]> <![CDATA[ aagcttgcatgcctgcag ]]> <![CDATA[ pNW_R ]]> <![CDATA[ cgttgcgctcactgcccg ]]> <![CDATA[ PmdhF ]]> <![CDATA[ ctgcaggcatgcaagctttcttttatatgaaaaaataaa ]]> <![CDATA[ BmilvDR ]]> <![CDATA[ agcgggcagtgagcgcaacgttagagcttcgatgtttc ]]> AL1-1 acaaaacttgatgtcaataagtg AL1-2 agaagacagaacatctacaac AL1-F gatatatgtaatatgggtcggg AL1-R cgttgagctaaaaggtttc AL2-1 ccacaggctttattggcag AL2-2 cggacgtggatgaaggtct AL2-F aaaagcgctcgtggtctaca AL2-R aaggcggcacgatcattgg AL3-1 gtgccgtgatcacagtcg AL3-2 acgatcgtgtctggcgtag AL3-F gagtatgcagtgctggtgc AL3-R ccaccacgcacaaccagg AL4-1 ttcaaactctagttcaagcga AL4-2 aggaaaatatcgatcatgtatagac AL4-F ggctcaacgagaatagctcc AL4-R caaaaagtgaaggatagaggc AL5-1 cactttcaaaaacgtagaattag AL5-2 ggatatgtgtttatgcttggc AL5-F gtactacagcatataacgtatg AL5-R ggatatacagatgcagattgg AL8-1 ttctctctcgaaacgtcgc AL8-2 ccagatctacatgcttgttgatc AL8-F aacttgtacggtgtgagc AL8-R cagcatatagaccagctgc

[0096] Example 1: Construction of Escherichia coli strain EMLEU00-08

[0097] The relevant strains were prepared according to the following steps (1)-(3):

[0098] (1) Construction of strain EMLEU01

[0099] Starting from Escherichia coli GL05, the promoter of the branched-chain amino acid transaminase gene ilvE (GenBank: NC_000913.3 (3952465-3952483) 09-DEC-2025) in this strain was replaced with the P119 promoter to obtain the EMLEU01 strain.

[0100] The specific steps are as follows:

[0101] (1-a) Preparation of the target fragment EMLEU-1

[0102] The synthesized DNA fragment is as follows: from 5' to 3', it consists of ilvEup, LKL (from 5' to 3', it consists of lox66, the Kan resistance gene, and lox71), and ilvEdown. Using ilvE-1 / ilvE-2 as primers, PCR amplification was performed with the synthesized DNA fragment as a template to obtain the targeting fragment EMLEU-1.

[0103] (1-b) Preparation of host bacteria containing pKD46 plasmid

[0104] The pKD46 plasmid was transformed into the originating *E. coli* GL05 via calcium chloride conversion. After overnight incubation on LB agar plates containing ampicillin at 30°C, clones were selected to obtain recombinant *E. coli* GL05 / pKD46 containing plasmid pKD46. Upon induction with arabinose, GL05 / pKD46 expressed three recombinant proteins of λ phage, thus endowing the host bacteria with homologous recombination capabilities. GL05 / pKD46 competent cells were then prepared by washing with 10% glycerol.

[0105] (1-c) Homologous recombination

[0106] The targeting fragment EMLEU-1 prepared in (1-a) was electroporated into GL05 / pKD46 competent cells prepared in (1-b). Cells were incubated overnight at 37°C on LB plates containing kanamycin (50 µg / mL). Clones were selected, and genomic DNA was extracted. PCR amplification was performed using ilvE-3 / Kan-R primers. A positive result (approximately 1000 bp target band) was observed, and the positive clone was named EMLEU01-kan. Sequencing analysis showed that the relevant target sequence on the genome of EMLEU01-kan was correct, and the promoter region of the ilvE gene was replaced with the P119 promoter. EMLEU01-kan was cultured overnight at 42°C to eliminate the temperature-sensitive plasmid pKD46.

[0107] (1-d) Elimination of resistance

[0108] The pSCre plasmid was transformed into the EMLEU01-kan strain, which had pKD46 eliminated, using the calcium chloride transformation method. The strain was incubated overnight at 30°C on LB agar plates containing 50 mg / L streptomycin and 0.2% L-arabinose. The kanamycin resistance fragment was eliminated using the Cre recombinase on the pSCre plasmid. The strain was then incubated overnight at 42°C to eliminate the temperature-sensitive pSCre plasmid. The resulting strain was named EMLEU01.

[0109] (2) Construction of strain EMLEU02

[0110] Using the same method as in Example 1 (1), strains EMLEU02-EMLEU06 were obtained from strain EMLEU01. The construction process for each strain was exactly the same as in Example 1 (1), except that different starting strains, targeting fragments, amplification primers, and identification primers were used. For details of the starting strains, targeting fragments, amplification primers, identification primers, and obtained strains involved in each step of the construction process from GL05 to EMLEU06, please refer to Table 3. The fragment sequences and primer sequences are shown in Tables 1 and 2, respectively.

[0111] Table 3. EMLEU01-EMLEU06 Construction Process

[0112] Step number Starting strain Target practice segment name The target shooting clip contains a sequence of segments (5'-3'). Modify target Amplification primers Identification primers Obtain strain 1 GL05 EMLEU-1 ilvEup, LKL, P119, ilvEdown Replace the promoter of the branched-chain amino acid transaminase gene (ilvE) with the P119 promoter. ilvE-1 / ilvE-2 ilvE-3 / KanR EMLEU01 2 EMLEU01 EMLEU-2 leuEup,LKL,P119,leuEdown Replace the promoter of the L-leucine transporter gene (leuE) with the P119 promoter. leuE-1 / leuE-2 leuE-3 / KanR EMLEU02 3 EMLEU02 EMLEU-3 yghXup, LKL, P119, ilvBN, TrrnB, yghXdown The hydrolase gene (yghX) was knocked out and replaced with the expression cassette of the acetolactate synthase gene (ilvBN). yghX-1 / yghX-2 yghX-3 / KanR EMLEU03 4 EMLEU03 EMLEU-4 livHup, LKL, P119, ilvC, RBS, ilvD, TrrnB, livHdown The branched-chain amino acid uptake protein gene (livH) was knocked out and replaced with expression cassettes of the acetyllactone isomer reductase gene (ilvC) and the hydroxy acid dehydratase gene (ilvD). livH-1 / livH-2 livH-3 / KanR EMLEU04 5 EMLEU04 EMLEU-5 lpxMup, LKL, Ptrc, pos5, TrrnB, lpxMdown The gene encoding myristyltransferase (lpxM) was knocked out and replaced with the expression cassette of the NADH kinase gene (pos5). lpxM-1 / lpxM-2 lpxMC-3 / KanR EMLEU05 6 EMLEU05 EMLEU-6 ackAup, LKL, P119, pgp1, RBS, hpdA1, TrrnB, Ptrc, xps1, TrrnB, ackAdown The gene encoding acetate kinase (ackA) was knocked out and replaced with expression cassettes for the genes encoding 3-phosphoglycerate phosphatase (pgp), hydroxypyruvate dehydrogenase (hpdA), and xylulose 5-phosphate synthase (xps). ackA-1 / ackA-2 ackA-3 / KanR EMLEU06

[0113] (3) Construction of production strain EMLEU07-08

[0114] The specific steps are as follows:

[0115] (3-a) Construction of plasmid pTrc99a-leu

[0116] Plasmids were constructed that overexpress the genes of isopropyl malate synthase leuA, isopropyl malate isomerase leuCD, and isopropyl malate dehydrogenase leuB.

[0117] A synthetically produced DNA fragment, with its 5' to 3' sequence being: leuA, RBS1, leuB, TrrnB, Ptrc, leuC, RBS1, leuD. Using leuA-F and leuD-R as primers, high-fidelity TransStart FastPfu DNA polymerase was used for PCR amplification, yielding the PCR product, denoted as E-leu. The target fragment E-leu was obtained by agarose gel electrophoresis and recovery. Using primers pTrc99a-01F and pTrc99a-01R, and plasmid pTrc99a (Beijing Zhuangmeng International Biotechnology Co., Ltd., catalog number ZK1610) as a template, the large vector fragment pTrc was amplified by PCR and recovered. The above fragments pTrc and E-leu were ligated using the Gibson assembly method (Gibson DG, Young L, et al. Enzymatic assembly of DNA molecules up to several hundredkilobases. Nat. methods. 2009; 6(5):343-345), and transformed into E. coli DH5α competent cells (purchased from Beijing Qingke Biotechnology Co., Ltd., product catalog TSC-C01). After recovery, the cells were evenly plated onto the corresponding antibiotic LB plates and cultured overnight at 37°C. Clones were picked, and PCR amplification using primers RV-M and pTrcHis-R was used to verify successful assembly, followed by sequencing. Positive clones were finally screened, and the plasmid was extracted and named pTrc99a-leu.

[0118] (3-b) Construction of the production strain EMLEU06

[0119] The plasmid pTrc99a-leu was transferred into the recombinant strain EMLEU05 obtained in step (2) of Example 1 by calcium chloride conversion. After overnight culture at 37°C on LB plates containing 100 µg / mL ampicillin, clones were selected to obtain the production strain containing plasmid pTrc99a-leu, which was named EMLEU07.

[0120] Following the steps above, starting from E. coli EMLEU06, plasmid pTrc99a-leu was introduced to obtain EMLEU08 strain.

[0121] Following the steps above, starting from Escherichia coli MG1655, plasmid pTrc99a-leu was introduced to obtain the EMLEU00 strain.

[0122] Example 2: Production of L-leucine using recombinant Escherichia coli EMLEU07 and EMLEU08

[0123] The test bacteria were recombinant Escherichia coli EMLEU07 and EMLEU08; the control bacteria was GL05.

[0124] The methanol culture medium used and its final concentrations are as follows: Na₂HPO₄: 25 mM, KH₂PO₄: 25 mM, NH₄Cl: 50 mM, Na₂SO₄: 5 mM, MgSO₄: 2 mM, methanol: 5 g / L, yeast extract: 0.5% (g / 100 mL). During the transformation process, methanol can be added to a final concentration of 5 g / L.

[0125] (1) The recombinant bacteria EMLEU06 and GL05, which had been cultured overnight, were inoculated at a rate of 1% into a shake flask containing 200 ml of LB medium and incubated at 37°C for 3-4 h until OD. 600 After the concentration of 0.6-0.8 nm was reduced, arabinose was added to a final concentration of 0.2 g / L. The cells were then incubated at 37 °C for 12 h and collected by centrifugation at 8000 rpm for 10 min.

[0126] (2) The collected bacterial cells were resuspended in shake flasks containing 10 mL of methanol conversion medium and converted at 200 rpm and 37 °C for 24 h. The supernatant was then collected by centrifugation. High performance liquid chromatography (HPLC) was used, and the specific method is as follows (2,4-dinitrofluorobenzene pre-column derivatization HPLC): 50 μL of the supernatant was placed in a 2 mL centrifuge tube, and 200 μL of NaHCO3 aqueous solution (0.5 mol / L, pH 9.0) and 100 μL of 1% 2,4-dinitrofluorobenzene-acetonitrile solution (volume ratio) were added. The mixture was heated in a 60 °C water bath in the dark for 60 min, then cooled to 25 °C. 650 μL of KH2PO4 aqueous solution (0.01 mol / L, pH 7.2 ± 0.05, pH adjusted with NaOH aqueous solution) was added. After standing for 15 min, the mixture was filtered and injected. The injection volume was 15 μL.

[0127] Testing instrument: SHIMADZU LC-20AT

[0128] Detection conditions: Mobile phase A: 10 mM KH2PO4; Mobile phase B: Acetonitrile-methanol-water solution (volume ratio 45:45:10); Detection wavelength: 360 nm; Detection time: 35 min; Detection temperature: 40 ℃; Flow rate: 1 mL / min; Column: Extnd-C18 (5 μm, 4.6 mm i.d. × 250 mm); Gradient elution: 1 min 12% B; 2.5 min 12% B; 2.51 min 16% B; 13 min 36% B; 13.01 min 38% B; 25 min 100% B; 28 min 100% B; 28.01 min 10% B; 35 min controller stops.

[0129] The results showed that the L-leucine yield of the control strain EMLEU00 was 0 g / L, that of strain EMLEU07 was 1.89±0.27 g / L, and that of strain EMLEU08 was 2.22±0.21 g / L. The constructed strains were able to effectively utilize methanol to synthesize xylitol.

[0130] The production characteristics of the relevant strains are shown in Table 4.

[0131] Table 4 Comparison of yields of different strains

[0132] strain Yield (g / L) EMLEU00 0 EMLEU07 1.89±0.27 EMLEU08 2.22±0.21

[0133] Example 3: Construction of Bacillus YWLEU00-06

[0134] The relevant strains were prepared according to the following steps (1)-(3):

[0135] (1) Construction of strain YWLEU01

[0136] Starting with Bacillus YW01, pflB was knocked out and replaced with expression cassettes of branched-chain amino acid transaminase gene BmilvE and L-leucine transporter gene leuE.

[0137] The specific steps are as follows:

[0138] (1-a) Construction of sequence substitution tool plasmid pYWCC12_pflB

[0139] Primers gpflB_F and gpflB_R were synthesized at a concentration of 10 μM. The primers were mixed at a volume ratio of 1:1, then boiled in a boiling water bath for 5 min and allowed to cool naturally to room temperature. This mixture was named gpflB_F / R.

[0140] Take the mixture gpflB_F / R and plasmid pYWCC12, and prepare the reaction solution according to the following system (the same applies below), where T4 DNA Ligase was purchased from NEB (catalog number M0202V), and BbsⅠ-HF was purchased from NEB (catalog number R3539S). The reaction system is as follows: T4 DNA Ligase Buffer (10×) 1μL, rCutSmart (10×) 1μL, T4 DNA Ligase (400U / μL) 0.65μL, BbsⅠ-HF (20U / μL) 1μL, gpflB_F / R 1μL, pYWCC12 20ng, and ddH2O to make up to 10μL.

[0141] After preparation and mixing, the mixture was incubated at 37°C for 1 hour, followed by incubation at 60°C for 5 minutes. After cooling on ice, it was transformed into *E. coli* DH5α competent cells. Positive clones were screened and sent to Qingke Biotechnology for sequencing verification, ultimately yielding the correct plasmid pYWCC12_pflB. pYWCC12_pflB is a recombinant vector obtained by replacing the nucleotide sequence between positions 8879 and 8910 of pYWCC12 with the nucleotide sequence gpflB (CTTGAAGGTCCGACTGAAGCTACA). pYWCC12_pflB expresses the Cas12a protein and sgRNA targeting the *Bacillus* YW01 pflB gene.

[0142] (1-b) Construction of plasmid pYWCC12_pflB&BmilvE-leuE

[0143] Using pYWCC12_pflB plasmid as a template and pYW_F and pYW_R as primers, the PCR product pYWCC12_pflB_BB was obtained by PCR amplification. Dpn I (NEB, catalog number R0176L) was added to the PCR product for digestion for 4 hours, and then the PCR product was recovered using a gel extraction kit to obtain the purified fragment pYWCC12_pflB_BB.

[0144] The synthesized DNA fragment is as follows: from 5' to 3', it consists of the following components: pflB_HRup, Pmdh, BmilvE, RBS2, leuE, and pflB_HRdw. Using pflB-F / pflB-R as primers for amplifying the target fragment, the synthesized DNA fragment was used as a template for PCR amplification to obtain the target fragment YC01.

[0145] Fragments YC01 and pYWCC12_Ppdh_BB were ligated using 2× MultiF Seamless Assembly Mix via Gibson assembly, transformed into DH5α competent cells, screened for positive clones, and sent to Qingke Biotechnology for sequencing verification, finally obtaining the correct plasmid pYWCC12_pflB&BmilvE-leuE.

[0146] (1-c) Preparation of competent cells

[0147] Bacillus YW01 was streaked on a nutrient medium plate and incubated overnight at 42°C. Freshly activated single colonies of YW01 were picked and placed in 10 mL of nutrient medium + 250 mM sucrose and incubated in a shaker at 42°C and 220 rpm for 16 h.

[0148] Take 1 mL of culture medium and inoculate it into an Erlenmeyer flask containing 50 mL of nutrient medium + 250 mM sucrose. Incubate at 42℃ and 220 rpm for 6-8 hours until OD (October Expiratory Response) occurs. 600 Approximately 0.8, then add glycine to a final concentration of 1% and continue culturing for 2 hours;

[0149] Incubate the bacterial culture on ice for 10 min, then centrifuge at 3000g to collect the bacterial cells. Resuspend the bacterial cells in 25 mL of buffer A (0.5 M D-sorbitol, 0.5 M D-mannitol, 10% glycerol), centrifuge at 3000g to collect the bacterial cells, and repeat this step twice. Finally, centrifuge and discard the supernatant. Resuspend the bacterial cells in 1 mL of buffer A and aliquot into 100 μL tubes for subsequent transformation experiments or freeze at -80℃ for later use.

[0150] (1-d) Transformation and positive clone screening

[0151] The competent cells were thawed on ice, and 1 μg of plasmid pYWCC12_pflB&BmilvE-leuE was added and transferred to an electroporation cuvette for 10 min on ice. Then, the cells were placed in an electroporator for electroporation (2.5 kV, 25 μF, 200 Ω).

[0152] The cells were then resuspended in 1 mL of preheated nutrient medium and revived at 42°C and 220 rpm for 6 h. After revival, the bacterial solution was centrifuged at 3000 g for 5 min at room temperature. The bacterial cells were collected and spread on nutrient medium plates containing chloramphenicol and incubated at 42°C for 2-3 days.

[0153] Clones were selected, and clones that could amplify the target fragment (approximately 4000 bp) were identified using primers pflB-U / pflB-D and sequenced. The positive strain was named YW01_pflB&BmilvE-leuE.

[0154] (1-e) Edit plasmid deletion

[0155] Single clones of YW01_pflB&BmilvE-leuE were picked and placed in nutrient medium, and cultured at 42℃ and 220 rpm for 16-24 hours. Then, they were transferred to fresh nutrient medium at a 1% inoculum rate and cultured at 50℃ and 220 rpm until OD reached. 600 The nm value was 1.5. The culture was subcultured 5 times at 50℃, and then streaked onto solid nutrient medium plates and cultured at 42℃ for about 36 hours.

[0156] Single colonies were selected and spotted onto solid nutrient media containing and without chloramphenicol, respectively. They were incubated at 42°C for 36 hours. Colonies that did not grow on chloramphenicol-containing plates but grew on non-chloramphenicol-containing plates were selected and preserved. This bacterium was named YWLEU01. This bacterium is the engineered bacterium YW01 with the pyruvate-formate lyase gene pflB knocked out and replaced with the branched-chain amino acid transaminase gene BmilvE and the L-leucine transporter gene leuE.

[0157] (2) Construction of strain YWLEU02

[0158] Using the same method as in Example 3(1), strains YWLEU01 was used to sequentially obtain strains YWLEU02, YWLEU03, and YWLEU04. The construction process for each strain was exactly the same as in Example 3(1), except that different N24 primers, targeting fragment amplification primers, and targeting fragments were used, resulting in different targeting plasmids. Different starting strains and identification primers were also used. The starting strains, N24 primers, targeting fragment amplification primers, targeting fragments, targeting plasmids, identification primers, and strain information involved in each step of the construction process from YW01 to YWLEU04 are detailed in Table 5. The fragment sequences and primer sequences are shown in Tables 1 and 2, respectively.

[0159] Table 5. Construction process of YWLEU01-YWLEU04

[0160]

[0161] (3) Construction of production strain YWLEU04

[0162] (3-a) Construction of plasmid pNW33N-leu

[0163] A synthetically produced DNA fragment, with its 5' to 3' sequence being: Pmdh, BmilvB, RBS2, BmilvH, Tmdh, Pmdh, BmilvC, RBS2, BmilvD. Using this DNA fragment as a template and PmdhF and BmilvDR as primers, PCR amplification was performed to obtain the B-leu fragment. The B-leu fragment was recovered by gel agarose gel electrophoresis.

[0164] Using pNW33N (purchased from Solarbio) plasmid as a template and pNW_F and pNW_R as primers, the PCR product pNW33N_BB was obtained by PCR amplification. Dpn I was added to the PCR product for digestion for 4 hours, and then the PCR product was recovered using a gel extraction kit to obtain the purified fragment pNW33N_BB.

[0165] Fragments B-leu and pNW33N_BB were ligated using 2× MultiF Seamless Assembly Mix via Gibson assembly, transformed into DH5α competent cells, screened for positive clones, and sent to Qingke Biotechnology for sequencing verification, finally obtaining the correct plasmid pNW33N-leu.

[0166] (3-b) Construction of production strain YWLEU05-06

[0167] The plasmid pNW33N-leu was transformed into strain YWLEU03 using the transformation method described in Example 3 (1) to obtain strain YWLEU05.

[0168] This transformation plasmid is a replication plasmid that can be stably replicated directly in YWLEU03 and its derived engineered bacteria and overexpress acetolactate synthase, acetolactate isomer reductase, and dihydroxy acid dehydratase under methanol-induced conditions.

[0169] Following the steps above, starting from YWLEU04, the plasmid pNW33N-leu was introduced to obtain strain YWLEU06.

[0170] Example 4: Production of L-leucine using Bacillus strains YWLEU05 and YWLEU06

[0171] The overnight cultured YW01, YWLEU05, YWLEU06 and YWLEU00 were inoculated at a rate of 1% into 200 mL of basal medium (pH=6.5) containing 10 g / L methanol and cultured on a shaker at 42°C for 36 hours. The culture products were then collected.

[0172] The culture product was centrifuged, and the supernatant was collected. After derivatization, the L-leucine content was determined by HPLC. The derivatization and analytical methods for L-leucine were the same as in Example 2.

[0173] The results showed that the supernatant yields of L-leucine produced by YW01, YWLEU00, YWLEU05, and YWLEU06 were 0.16±0.04 g / L, 0.49±0.08 g / L, 2.57±0.21 g / L, and 2.82±0.37 g / L, respectively.

[0174] The production characteristics of the relevant strains are shown in Table 6.

[0175] Table 6. Comparison of yields of different strains

[0176] strain Yield (g / L) YW01 0.16±0.04 YWLEU00 0.49±0.08 YWLEU05 2.57±0.21 YWLEU06 2.82±0.37

[0177] Example 5: Construction of yeast ALEU00-08

[0178] The relevant strains were prepared according to the following steps (1)-(2):

[0179] (1) Enhance the expression of the acetolactate synthase (Opals) gene by increasing the gene copy number.

[0180] (1-a) Construction of plasmid pPCCas-gCIS1:

[0181] The opaCIS1 was chosen as the insertion site, its position on the chromosome of *Hansenula polymorpha* strain AP17 corresponding to the HPODL_01995 and HPODL_01996 genes on the chromosome of the initial strain DL-1. A synthetic DNA fragment (Kangwei Century Company) was used: the recognition fragment SgCIS1. Bases 62-81 of this fragment correspond to the N20 sequence (5'-aaccaacacaccttcatatc-3') corresponding to the opaCIS1 insertion site, and the remaining bases are the sgRNA backbone sequence. The synthesized recognition fragment was directly cloned into the pUC57 vector to obtain the plasmid pUC57-SgCIS1.

[0182] The construction of the tool plasmid pPCCas-CIS1 was performed using the following ligation reaction system: 1 μL T4 DNA Ligase Buffer (10×), 1 μL rCutSmart (10×), 0.65 μL T4 DNA Ligase, 1 μL BbsⅠ-HF, 20 ng pPCCas plasmid, 140 ng pUC57-gCIS plasmid, and ddH2O to a final volume of 10 μL. The reaction was carried out at 37℃ for 1 h, followed by 60℃ for 5 min. The cells were then transformed into *E. coli* DH5α competent cells, plated on LB agar plates containing ampicillin, and incubated overnight at 37℃. Positive clones were selected and directly sequenced to verify their identity. The plasmid sequence of the positive clone was obtained by replacing positions 7012-7090 of the pPCCas plasmid with positions 13-83 of the recognition fragment SgCIS1. The positive clone plasmid was named pPCCas-CIS1.

[0183] (1-b) Preparation of the target fragment CIS1-ALS

[0184] The artificially synthesized DNA fragment (Kangwei Century Company) consists of the following sequences from 5' to 3': CIS1up, PMOX, Opals1, TMOX, PMOX, Opals2, TMOX, and CIS1down. PMOX is the strong promoter Pmox gene sequence, and TMOX is the termination regulatory region Tmox gene sequence. Using AL1-1 / AL1-2 as amplification primers and the synthesized DNA fragment as a template, PCR amplification was performed to obtain the targeted fragment CIS1-ALS, which was then recovered via agarose gel.

[0185] (1-c) Transformation and identification of recombinant strains

[0186] The *Hansenula polymorpha* AP17 strain was transferred to 100 mL of liquid YPD medium and cultured at 37°C and 220 r / min until OD200. 600 The nm value was 1.3-1.5. The cells were then collected by centrifugation at 1500g and 4℃ for 5 min. After resuspending in 40 mL of pre-cooled sterile water, the cells were centrifuged again. The cells were washed twice with 20 mL of pre-cooled 1 M sorbitol and finally resuspended in 600 μL of pre-cooled 1 M sorbitol to prepare competent cells.

[0187] 50 ng of plasmid pPCCas-CIS1 and 100 ng of the targeting fragment CIS1-ALS were added to 80 μL of the above competent cells, and electroporation was performed using a suitable electroporator. Immediately after electroporation, 1 mL of YPD medium was added, and the cells were incubated statically at 37°C for 2 h. The cells were then plated on YPD agar plates containing bleomycin and incubated at 37°C for 2 days. Single clones were picked from the plates, transferred to YPD medium, and cultured with shaking at 37°C. PCR amplification was performed using the identification primers AL1-F / AL1-R. The PCR products were directly sequenced for identification; clones containing the complete targeting fragment sequence were considered positive.

[0188] Positive clones were streaked onto antibiotic-free YPD plates. Single colonies were picked and inoculated into YPD liquid medium, incubated at 37°C, and passaged three times. The colonies were then streaked again onto YPD plates. Single colonies were selected, and strains that could not grow on bleomycin-containing YPD medium were selected and named ALEU01. This strain is a recombinant Hansenula polymorpha with acetolactate synthase (ALS) inserted at the opaCIS1 site on the chromosome.

[0189] (2) Construction of strain ALEU02-ALEU06

[0190] Using the same method as in Example 5(1), strains ALEU02-ALEU06 were obtained sequentially from strain ALEU01. The construction process of each strain was exactly the same as in Example 5(1), except that different starting strains, recognition fragments, tool plasmids, amplification primers, targeting fragments, and identification primers were used. The starting strains, recognition fragments, tool plasmids, amplification primers, targeting fragments, identification primers, and information on the obtained strains involved in each step of the construction process from strain AP17 to strain ALEU06 are detailed in Table 7. The fragment sequences and primer sequences are shown in Tables 1 and 2, respectively.

[0191] Table 7. Construction process of ALEU01-ALEU06

[0192]

[0193] Example 6: Production of L-leucine using yeast ALEU05 and ALEU0506

[0194] (1) Preparation of culture medium

[0195] The culture medium formula for growth is as follows: 26.7 mL phosphate, 0.93 g calcium sulfate, 18.2 g potassium sulfate, 14.9 g magnesium chloride heptahydrate, 4.13 g potassium hydroxide, 20.0 g glycerol, 12 mL trace elements, and distilled water to a final volume of 1 L.

[0196] Trace element formula: 6.0 g copper sulfate pentahydrate, 0.08 g sodium iodide, 3.0 g manganese sulfate monohydrate, 0.2 g sodium molybdate dihydrate, 0.02 g boric acid, 0.5 g cobalt chloride, 20.0 g zinc chloride, 65.0 g ferrous sulfate heptahydrate, 0.2 g biotin, 5.0 mL sulfuric acid, and distilled water to a final volume of 1 L.

[0197] The conversion medium formula is: disodium hydrogen phosphate 25 mM, potassium dihydrogen phosphate 25 mM, ammonium chloride 100 mM, methanol 5%, and trace elements 12 mL / L.

[0198] (2) Culture of bacterial cells and induction of enzymes

[0199] The AP17 cells (recipient yeast) cultured overnight, the engineered strains ALEU05 and ALEU06 were inoculated at a rate of 1% into shake flasks containing 200 mL of growth medium, and cultured at 30°C for 1 day to obtain fermentation broth. The cells were collected by centrifugation to obtain AP17, ALEU05 and ALEU06 cells respectively.

[0200] (3) Whole-cell catalysis of L-leucine

[0201] The experiment was repeated three times, with the following steps repeated each time: Bacterial cell treatment: OD 600 The bacterial cell weight of 20 was suspended in a 100 mL Erlenmeyer flask containing 20 mL of transformation medium and incubated at 30°C for 72 h. After centrifugation, the supernatant was collected, derivatized, and then analyzed by HPLC to determine the L-leucine content. The derivatization and analytical methods for L-leucine were the same as in Example 2.

[0202] The results are shown in Table 8. The L-leucine yield of AP17 was 0.10±0.06 g / L, while the L-leucine yields of ALEU05 and ALEU06 were 1.15±0.07 g / L and 1.88±0.23 g / L, respectively.

[0203] Table 8 Comparison of yields of different strains

[0204] strain Yield (g / L) AP17 0.10±0.06 ALEU05 1.15±0.07 ALEU06 1.88±0.23

Claims

1. A recombinant bacterium, characterized in that: The recombinant bacteria can synthesize L-leucine using methanol as a raw material.

2. The recombinant bacteria according to claim 1, characterized in that: The recombinant bacteria were obtained by modifying the starting strain by at least one of the following methods: A1) Enhance the gene expression level of acetolactate synthase, and / or enhance its enzyme activity or content; A2) Enhance the gene expression level of acetolactate isomer reductase, and / or enhance its enzyme activity or content; A3) Enhance the gene expression level of dihydroxy acid dehydratase, and / or enhance its enzyme activity or content; A4) Enhance the gene expression level of isopropyl malate synthase, and / or enhance its enzyme activity or content; A5) Enhance the gene expression level of isopropyl malate isomerase, and / or enhance its enzyme activity or content; A6) Enhance the gene expression level of isopropyl malate dehydrogenase, and / or enhance its enzyme activity or content; A7) Enhance the gene expression level of branched-chain amino acid transaminases, and / or enhance their enzyme activity or content; A8) Introduce the L-leucine efflux protein gene and / or introduce a substance with the activity of this protein; A9) Introduce the NADH kinase gene and / or introduce a substance with the activity of this enzyme.

3. The recombinant bacteria according to claim 1 or 2, characterized in that: The recombinant bacteria also include at least one of the following operations performed on the starting strain: B1) Introduce the 3-phosphoglycerate phosphatase gene and / or introduce a substance with the activity of this enzyme; B2) Introduce the hydroxypyruvate reductase gene and / or introduce a substance with the activity of this enzyme; B3) Introduce the xylulose 5-phosphate synthase gene and / or introduce a substance with the activity of this enzyme.

4. The recombinant bacteria according to any one of claims 1 to 3, characterized in that: The starting strain is a strain with methanol tolerance characteristics; the strain with methanol tolerance characteristics is selected from at least one of the following strains: Ogataea parapolymorpha AP17 (CGMCC No. 39154); Escherichia coli GL05 (CGMCC No. 35139); Bacillus sp. YW01 (accession number: CGMCC No. 37312).

5. The use of the recombinant bacteria according to any one of claims 1 to 4 in the preparation of L-leucine.

6. A method for preparing L-leucine, characterized in that: The method includes using the recombinant bacteria of any one of claims 1 to 4 as the fermentation strain, and using methanol as the raw material to ferment and prepare L-leucine.

Citation Information

Patent Citations

  • Construction and application of recombinant escherichia coli

    CN120485085A

  • Bacillus capable of tolerating various organic solvents and application thereof

    CN120519332A

  • Construction and application of methanol utilization engineering escherichia coli

    CN122521498A

  • Bacillus strain with high methanol utilization and application thereof

    CN122879114A